• About us
• Contact

Advertisement

Person › Details

Holger Zimmermann (AiCuris GmbH & Co. KG)

Zimmermann, Holger (AiCuris 202304– Chief Research + Development Officer before CEO before CSO)

 

	Organisation	AiCuris GmbH & Co. KG
	Group	STRÜNGMANN Group (family Strüngmann)
	Product	virostatic agent

Record changed: 2023-10-03

Advertisement

More documents for Holger Zimmermann

• [1] AiCuris Anti-infective Cures AG. (4/4/23). "Press Release: AiCuris AG Announces Appointment of Larry Edwards as Chief Executive Officer and Formation of U.S. Subsidiary". Cambridge....
• [2] AiCuris Anti-infective Cures AG. (2/9/22). "Press Release: AiCuris and Hybridize Therapeutics Enter Worldwide License Agreement of up to €100M for a Direct-acting RNA-based Therapy against BK Virus". Wuppertal & Leiden....
• [3] AiCuris Anti-infective Cures AG. (7/8/21). "Press Release: AiCuris Starts Its First Pivotal Clinical Phase 3 Trial with Pritelivir for the Treatment of Herpes Simplex Virus Infections in Immunocompromised Subjects". Wuppertal....
• [4] AiCuris Anti-infective Cures AG. (5/25/21). "Press Release: AiCuris AG Announces Dr. Stefan Oschmann, Former Merck CEO, to Chair the AiCuris Supervisory Board". Wuppertal....
• [5] AiCuris Anti-infective Cures GmbH. (6/9/20). "Press Release: Royalty Pharma Acquires Partial Royalty Interest on Prevymis (Letermovir) from AiCuris Anti-infective Cures GmbH". New York, NY & Wuppertal....
• [6] AiCuris Anti-infective Cures GmbH. (7/9/19). "Press Release: AiCuris and Lysando Join Forces in the Fight against Antimicrobial Resistance". Wuppertal & Balzers....
• [7] AiCuris Anti-infective Cures GmbH. (10/1/18). "Press Release: AiCuris to Cooperate with Cyclenium Pharma to Develop Novel Anti-Infectives". Wuppertal & Montreal....
• [8] AiCuris Anti-infective Cures GmbH. (9/3/18). "Press Release: AiCuris Reports Positive Phase 1 Clinical Trial Results with Immunomodulator AIC649 in Patients with Chronic Hepatitis B". Wuppertal....
• [9] AiCuris Anti-infective Cures GmbH. (4/25/18). "Press Release: Approval of MSD’s Prevymis (letermovir) in Japan Triggers EUR 15 Million Milestone Payment for AiCuris". Wuppertal....
• [10] AiCuris Anti-infective Cures GmbH. (4/18/18). "Press Release: AiCuris and Max Planck Institute of Molecular Physiology Join Forces in the Field of Anti-infectives". Wuppertal & Dortmund....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.